Register for the upcoming healthbook Event

Thursday, November 12, 2026
from 15:00 – 18:15 CET

FFHS Gleisarena
Zollstrasse 11
8005 Zurich

Chairs

Prof. Christoph Renner
Clinic Hirslanden, Zurich

Prof. Ulrich Mey
Cantonal Hospital Graubünden, Chur

Speakers

Prof. Paul Richardson
Dana-Farber Cancer Institute, Boston MA, USA

Dr Martina Bertschinger
University Hospital Inselspital Bern
Winterthur Cantonal Hospital

Dr Rouven Müller
University Hospital Zurich

Scientific Flow

15:00 – 15:05	Welcome & Introduction Chair: Christoph Renner
15:05 – 15:45	Keynote Lecture Multiple Myeloma 2026 – Redefining the Treatment Landscape: ADCs, CAR T Cells, Bispecific Antibodies, PDCs, and Novel Small Molecules including CELMoDs Speaker: Paul Richardson Q&A Session Moderator: Christoph Renner
15:45 – 16:15	Session 1 Frontline and Early Relapse – Practical Sequencing • Transplant-eligible versus non-eligible patients • Maintenance strategies and MRD thinking Speaker: Christoph Renner Expert panel discussion Moderator: Ulrich Mey Panel: Paul Richardson, Faculty
16:15 – 16:35	Interactive Case Board I: First Relapse Decision Making • Case 1: First relapse – Real-world case presentation • Live audience voting (decision points) • Expert panel discussion Speaker: Martina Bertschinger Moderator: Christoph Renner Panel: Paul Richardson, Ulrich Mey, Faculty
16:35 – 17:00	Networking Coffee Break
17:00 – 17:30	Educational Focus Session: Antibody-Drug Conjugates and CELMoDs as “Off the Shelf” Novel Therapies in RRMM: From Belantamab Mafodotin to the Emergence of CELMoDs and Beyond Speaker: Paul Richardson Q&A Session Moderator: Christoph Renner
17:30 – 17:50	Interactive Case Board II: Triple-Class Exposed/Post-BCMA Treatment Strategies • Case 2: Post-BCMA; complex relapsed/refractory case • Live voting and expert discussion Speaker: Rouven Müller Moderator: Ulrich Mey Panel: Paul Richardson, Christoph Renner, Faculty
17:50 – 18:05	Expert Panel: Myeloma Controversies 2026 Rapid-Fire Moderated Discussion with Audience Polling • Optimal sequencing of immune-based therapies, ADCs and CELMoDs • Role of MRD in routine practice • Future positioning of CAR T cells, bispecific antibodies, ADCs and CELMoDs Moderators: Christoph Renner, Ulrich Mey Panel: Paul Richardson, Faculty
18:05 – 18:15	Take-Home Messages & Closing Chair: Christoph Renner
18:15	Onsite Networking Reception